Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC
Richard S. Finn, MD, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma.
Richard S. Finn, MD, professor of Clinical Medicine Division of Hematology/Oncology, UCLA David Geffen School of Medicine, University of California, Los Angeles, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma (HCC).
Both sorafenib (Nexavar) and lenvatinib (Lenvima) have been approved by the FDA for the treatment of patients with advanced HCC in the frontline setting. The REFLECT trial that compared the 2 agents was a noninferiority trial, so Finn says neither agent is superior to the other.
According to both traditional and modified RECIST criteria, lenvatinib has a higher response rate, but no drug has ever been able to beat the survival rates seen with sorafenib, Finn notes. Data from the REFLECT study showed that if a patient has a response with either agent, that could provide a survival of 22 months, or even more in select patient populations.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
